Hepatitis B virus infection in northern Uganda: Impact of pentavalent hepatitis B vaccination

被引：8

作者：

Teshale, Eyasu H. ^{[1
]}

Kamili, Saleem ^{[1
]}

Drobeniuc, Jan ^{[1
]}

Denniston, Maxine ^{[1
]}

Bakamutamaho, Barnabas ^{[2
]}

Downing, Robert ^{[2
]}

机构：

[1] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA

[2] Uganda Virus Res Inst, Entebbe, Uganda

来源：

VACCINE | 2015年 / 33卷 / 46期

关键词：

Hepatitis B virus; Pentavalent vaccine; Prevalence; Birth-dose; Mother-to-infant transmission;

D O I：

10.1016/j.vaccine.2015.09.058

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chronic hepatitis B virus infection (CHBI) is effectively prevented by vaccination starting at birth. Beginning in 2002 Uganda adopted a policy of providing the pentavalent hepatitis B vaccine starting at 6 weeks of age. However, there is concern that this delay may leave the infant vulnerable to infection during the first 6 weeks of life. We assessed whether vaccination at 6 weeks was an effective strategy by HBV serologic study. Of 656 persons tested for HBV, 9.4% were chronically infected; among children aged 5-9 years the prevalence was 7.6%. Of all tested, 73 were born (i.e., aged <= 4 years) after the introduction of the pentavalent vaccine; none were infected with HBV (p = 0.003). In this study, vaccination with the pentavalent vaccine at 6 weeks did not result in CHBI, but rather provides an opportunity to prevent mother-to-infant transmission of HBV infection where there is no access to birth-dose vaccine. (C) 2015 Published by Elsevier Ltd.

引用

页码：6161 / 6163

页数：3